What are the possible physical reactions after taking ibrutinib/ibrutinib?

Ibrutinib/Ibrutinib, also known as Imbruvica, is a targeted anti-cancer drug that is widely used to treat a variety of B-cell malignancies, such as mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia. As a tyrosine kinase inhibitor (TKI), ibrutinib inhibits the growth and division of tumor cells by blocking intracellular tyrosine kinase activity.

However, despite its excellent performance in anti-tumor treatment, long-term use of ibrutinib may also cause a series of adverse effects. These reactions are primarily caused by the drug's broad inhibitory effects on targeted and non-targeted tyrosine kinases. Common side effects include skin problems, high blood pressure, susceptibility to infections, diarrhea, joint pain, etc. In addition, cardiotoxicity and bleeding tendencies are also adverse effects of concern. Cardiotoxicity, in particular, may manifest as arrhythmia symptoms such as atrial fibrillation, while severe bleeding may be life-threatening.

It is important to note that each patient may respond differently to ibrutinib. Therefore, while taking ibrutinib, patients should pay close attention to their physical condition and promptly report any discomfort or abnormal reactions to their doctor. The doctor will adjust the treatment plan based on the patient's specific situation and drug response, such as adjusting drug dosage or taking other necessary supportive treatment measures to ensure the safety and effectiveness of the treatment.

In short, although ibrutinib has achieved remarkable results in the treatment ofB-cell tumors, patients still need to be alert to possible side effects during use and maintain close communication with their doctors to jointly develop a treatment plan that is most suitable for them.